Elstar Therapeutics and King’s College London Enter Immuno-Oncology Research Collaboration


Cambridge, MA, August 5, 2020—Elstar Therapeutics and King’s College London have embarked on a strategic collaboration to conduct research into T-cell activation and regulation. The basic research activities will be conducted by scientists from Elstar and King’s College London, under the supervision of Professor Adrian Hayday, Kay Glendinning Professor of Immunobiology at King’s College London. The two-year research collaboration seeks to study the immunological effects of Elstar’s novel T-cell engager antibodies.

“We are pleased to be partnering with Professor Hayday’s lab at King’s College London, one of the world’s pre-eminent immunology research laboratories, on work that we believe will advance our understanding of how our novel T-cell engagers impact T-cell phenotype and function,” said Andrew Bayliffe, Chief Scientific Officer of Elstar Therapeutics and venture partner at Apple Tree Partners. “Our aim is to learn more about how we may selectively and safely promote the activation of defined T-cell subsets, with implications for treatment in cancer and other disease settings.”